Skip to main content
TipRanks
Go Ultimate75% OFF

ADMA Biologics (ADMA) Q3 2026 Earnings Report

3,063 Followers

ADMA Q3 2026 EPS Results

Actual EPS
$0.23
Consensus EPS
$0.20
Beat/Miss
Beat by +$0.03
One Year Ago EPS
$0.16

ADMA Q3 2026 Revenue Results

Actual Revenue
$141.10M
Expected Revenue
$138.11M
Beat/Miss
Beat by +$2.99M
YoY Revenue Growth
+5.12%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/04/2026
Time
After Close
Conference Call
Wednesday, November 4, 2026
ADMA Upcoming Earnings

ADMA Biologics's next earnings date is estimated for March 25, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

ADMA Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 04, 2026|% Change Since:30.53%|
Earnings Call Sentiment|Positive

The call was strongly positive overall. ASCENIV delivered accelerating revenue growth, expanded margins, substantial earnings and cash-flow growth, and durable patient-demand indicators. The company raised minimum adjusted EBITDA and adjusted net income guidance, continued significant share repurchases, and reported constructive FDA feedback for SG-001. The main challenges were BIVIGAM's revenue decline, persistent pricing and competitive pressure in the standard IG market, moderate secondary immunodeficiency growth, and DSOs remaining above the target range.

Company Guidance

The company reiterated full year 2026 revenue guidance of at least $530 million, increased minimum adjusted EBITDA guidance to at least $275 million from $265 million previously, and increased minimum adjusted net income guidance to at least $180 million from $170 million previously; it continues to execute against a target of $200 million or more in total share repurchases during 2026. Management said ASCENIV month-to-month growth remains within the previously stated 2% to 4% growth expectation and estimated full-year growth at about 25%, maybe a little more than that, while SG-001 represents a potential $300 million to $500 million annual revenue opportunity. The DSO target remains between 90 to 105 days, Q4 R&D spend is expected to be probably close to $10 million, and management expects to provide firm clinical timelines sometime next year.

  • ASCENIV Revenue Growth AcceleratedThird-quarter ASCENIV revenue reached $124.7 million, increasing 31% year-over-year and 21% sequentially. Growth was driven by broader physician adoption, new patient starts, increasing end-user utilization, medical education activities, real-world evidence, and expanded sales-force presence.
  • Total Revenue IncreasedThird-quarter total revenue was $141.1 million, up 5% year-over-year from $134.2 million and 13% sequentially from $124.4 million.
  • Strong Gross Margin ExpansionGross profit increased to $99.9 million from $75.6 million a year ago and $86.3 million in the second quarter. Gross margin reached 71%, compared with 56% a year ago and 69% in the second quarter, representing approximately 1,450 basis points of year-over-year expansion. Favorable ASCENIV mix and yield-enhanced manufacturing were the principal drivers.
  • Adjusted EBITDA Growth and Operating LeverageAdjusted EBITDA was $77.3 million, increasing 32% year-over-year and 25% sequentially. Adjusted EBITDA for the first nine months totaled $198.8 million, with profitability growth exceeding revenue growth.
  • Net Income and EPS GrowthGAAP net income reached $49.9 million, increasing 37% year-over-year and 32% sequentially. Adjusted net income was $51.1 million, up approximately 31% both year-over-year and sequentially. GAAP basic EPS was $0.22, up 47% year-over-year and 29% sequentially, while adjusted basic EPS was $0.23, up 44% year-over-year and 35% sequentially.
  • Full-Year Revenue and Earnings Guidance RaisedThe company reiterated full-year 2026 revenue guidance of at least $530 million. Minimum adjusted EBITDA guidance increased to at least $275 million from $265 million previously, and minimum adjusted net income guidance increased to at least $180 million from $170 million previously.
  • ASCENIV Maintains Durable Patient DemandThe company reported increasing prescriber numbers, new patient starts, durable recurring patient demand, and patients remaining on therapy. Management stated that the average percentage of patients staying on therapy for a year or longer has been increasing and that ASCENIV remains early in its penetration curve.
  • Primary Immunodeficiency Remains the Main Growth DriverPrimary immunodeficiency continued to lead ASCENIV growth. Management identified a 25,000-patient target market, approximately 10% of the total 250,000-patient primary immunodeficiency population, and stated that penetration is above the previously reported level of approximately 4%.
  • ASCENIV Commercial Coverage Remained StrongThe company reported broad commercial-plan coverage for ASCENIV, growth in the commercial payer landscape, good coverage across geographies, and no third-quarter changes to reimbursement. Management stated that appropriate use cases were not experiencing difficulties obtaining commercial payer reimbursement.
  • ASCENIV Remained Largely Insulated from Standard IG OversupplyManagement stated that ASCENIV continues to be largely insulated from the standard immunoglobulin market's oversupply pressures because the company is focusing on appropriate-use-case patients and is seeing good utilization and durable recurring demand month over month.
  • Real-World Outcomes Evidence ExpandedAt the upcoming ACAAI Annual Conference, ADMA plans to present real-world health outcomes data from 127 medically complex primary immunodeficiency patients. Comparing the 12 months before and after ASCENIV initiation, the analysis identified statistically significant reductions in infection-related hospitalizations, outpatient health care utilization, oral antibiotic use, and corticosteroid use.
  • BIVIGAM Utilization Showed Stabilization SignsAlthough reported BIVIGAM revenue declined, management said underlying end-user utilization showed encouraging signs of stabilization entering the fourth quarter, including a rebound as the company exited the third quarter. The company continues to prioritize sustainable commercial participation rather than matching aggressive competitor rebating and discounting.
  • BIVIGAM Scientific Differentiation AdvancedRecently published peer-reviewed research examining thrombosis-related product attributes was described as an advancement in ADMA's scientific differentiation strategy. Management stated that the research provides objective scientific evidence to support product evaluations and adds differentiation for BIVIGAM in the U.S. standard immunoglobulin market.
  • SG-001 Development ProgressedADMA advanced SG-001, its investigational pneumococcal hyperimmunoglobulin candidate, through preclinical assay development and manufacturing-readiness activities. ADMAlytics uses computational modeling, artificial intelligence, and predictive analytics to forecast final titer values from limited experimental data.
  • Constructive FDA Feedback for SG-001The FDA provided constructive feedback on the SG-001 pre-IND meeting package, including the proposed clinical development strategy and key elements of the planned clinical study. The FDA indicated that the proposed assay would be acceptable for product testing subject to appropriate validation. ADMA intends to incorporate the recommendations into the final clinical protocol and advance preparations for an IND submission.
  • SG-001 Represents a Potential Large Revenue OpportunityManagement continues to believe SG-001 represents a potential $300 million to $500 million annual revenue opportunity and stated that the program may leverage ADMA's established manufacturing capabilities, clinical development experience, production and laboratory infrastructure, and ADMAlytics predictive modeling capabilities.
  • Cash Generation and Liquidity StrengthenedCash and cash equivalents totaled approximately $124.6 million as of September 30, 2026. Cash and cash equivalents increased approximately $36.9 million during the first nine months despite significant share repurchases. Cash from operations was $105 million year-to-date through September 30, an increase of over 600% versus the first nine months of 2025. Net leverage remained under half a turn.
  • Share Repurchases ContinuedDuring the first nine months of 2026, ADMA repurchased $181.4 million of stock, representing 16.5 million shares and a reduction of approximately 6.3% in shares outstanding compared with year-end 2025. The company continues to execute against its target of $200 million or more in total share repurchases during 2026.
  • Research and Development Program ContinuedResearch and development expense was approximately $4.5 million in the third quarter, compared with $1.5 million a year ago and $6 million in the second quarter, as the company continued SG-001 development with lower sequential plasma collection activity. The company expects to produce SG-001 performance lots in the fourth quarter, with quarterly R&D spend expected to be close to $10 million because of additional plasma costs and manufacturing.
  • Manufacturing and Plasma Sourcing Capabilities Supported ProfitabilityManagement cited yield-enhanced manufacturing, diversified plasma sourcing, disciplined spending, manufacturing quality, and established production infrastructure as foundations for profitability, cash generation, and continued product-specific commercial execution.

ADMA Earnings History

ADMA earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 25, 20272026 (Q4)0.24-0.21――
Nov 04, 20262026 (Q3)0.200.230.1640.63% (+0.07)
Aug 05, 20262026 (Q2)0.160.170.1512.24% (+0.02)
May 06, 20262026 (Q1)0.190.170.1425.74% (+0.04)
Feb 25, 20262025 (Q4)0.180.210.1451.06% (+0.07)
Nov 05, 20252025 (Q3)0.150.160.16-1.84% (-0.00)
Aug 06, 20252025 (Q2)0.140.150.143.52% (+0.01)
May 07, 20252025 (Q1)0.150.140.0952.81% (+0.05)
Mar 03, 20252024 (Q4)0.150.14-0.08276.25% (+0.22)
Nov 07, 20242024 (Q3)0.130.160.011530.00% (+0.15)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed